… benefits of first-line treatments for Asian patients with advanced epidermal growth factor receptor-mutated NSCLC harboring exon 19 deletion: a systematic review …
SK Chan, HCW Choi, VHF Lee - Cancers, 2022 - mdpi.com
… Erlotinib plus bevacizumab, ramucirumab plus erlotinib, and … reported in Asia, with non-small-cell
lung cancer (NSCLC) as … out a well-designed phase III, multicenter RCT, which makes …
lung cancer (NSCLC) as … out a well-designed phase III, multicenter RCT, which makes …
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials
… of erlotinib as a first-line treatment for EGFR mutation-positive … of ramucirumab plus erlotinib
with that of erlotinib alone in … is a multicenter, randomized, double-blind, phase 3 clinical trial …
with that of erlotinib alone in … is a multicenter, randomized, double-blind, phase 3 clinical trial …
… Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non …
M Mosca, N Conci, A Di Federico, V Tateo… - JCO Precision …, 2023 - ascopubs.org
… inhibitor or anti-EGFR or erlotinib or dacomitinib or gefitinib or … inhibitor or bevacizumab or
ramucirumab or VEGFR inhibitor … these trials since we demonstrated that brain metastases are …
ramucirumab or VEGFR inhibitor … these trials since we demonstrated that brain metastases are …
… Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth …
Y Okuma, Y Shintani, I Sekine, T Shukuya… - Clinical Lung Cancer, 2024 - Elsevier
… good-PS patients with EGFR mutation-positive advanced NSCLC… or increased incidence of
erlotinib-related toxicities. … specific reasons for poor PS were not clarified in the current study. …
erlotinib-related toxicities. … specific reasons for poor PS were not clarified in the current study. …
Erlotinib and bevacizumab in elderly patients≥ 75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations
Y Aoshima, M Karayama, N Inui, H Yasui… - Investigational New …, 2021 - Springer
… , six patients had previously treated stable brain metastases. … in elderly patients with
EGFR mutation-positive NSCLC. The … plus gefitinib, or erlotinib plus ramucirumab [25,26,27,28,29]. …
EGFR mutation-positive NSCLC. The … plus gefitinib, or erlotinib plus ramucirumab [25,26,27,28,29]. …
Response to: The Role of Dual Inhibition of EGFR and Vascular EGF (R) in the Treatment of NSCLC With EGFR Mutation
H Zhao, Z Zhang, L Zhang - Journal of Thoracic Oncology, 2021 - jto.org
… analysis, well-designed prospective clinical studies are needed to answer … mutation-positive
non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial…
non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial…
… -mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study
L Zhang, L Wang, J Wang, J Chen, Z Meng, Z Liu… - Molecular Cancer, 2023 - Springer
… first-line treatment of EGFR mutation-positive advanced NSCLC. … or mildly symptomatic brain
metastases; and life expectancy … in the ramucirumab plus erlotinib group compared with the …
metastases; and life expectancy … in the ramucirumab plus erlotinib group compared with the …
Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
… the feasibility of combining erlotinib and angiogenesis for … pretreated patients with EGFR
mutation-positive lung cancer was … This study is currently enrolling patients with metastatic EGFR…
mutation-positive lung cancer was … This study is currently enrolling patients with metastatic EGFR…
[HTML][HTML] Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC
X Le, M Nilsson, J Goldman, M Reck… - Journal of Thoracic …, 2021 - Elsevier
… RELAY trial, a large global, placebo-controlled, double-blind trial, evaluated the effects of
erlotinib plus ramucirumab versus erlotinib plus placebo in 449 patients with metastatic NSCLC…
erlotinib plus ramucirumab versus erlotinib plus placebo in 449 patients with metastatic NSCLC…
[PDF][PDF] A Patient With Newly Diagnosed, Advanced EGFR-Mutated Non–Small Cell Lung Cancer
L Lara-Mejía, R Sánchez-Reyes… - Oncology (Williston …, 2020 - researchgate.net
… of erlotinib and ramucirumab versus erlotinib alone in the … Patients with brain metastases
were excluded from the study. … mutation-positive NSCLC who received sequential treatment …
were excluded from the study. … mutation-positive NSCLC who received sequential treatment …